Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

NCT02977780 is registered in ClinicalTrials.gov with David Reardon, MD as lead sponsor.

NCT NCT02977780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02977780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Lead sponsor
David Reardon, MD
Phase
Phase 2
Overall status
Recruiting
Start date
February 9, 2017
Completion date
April 30, 2028
Enrollment
460 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma